Dr Reddy's launches authorised generic of Vasostrict injection

Dr. Reddy’s on Wednesday said it has launched authorized generic version of Par Pharmaceutical’s Vasostrict (vasopressin injection) vials in the US market. Authorised generic is a licensed copy of the branded version.

Vasopressin injection is used to treat diabetes insipidus, a condition that causes the body to lose too much water and become dehydrated.

“We are pleased to provide this important authorized generic product to patients, especially in these difficult times of COVID-19,” says Marc Kikuchi, CEO of North America Generics, Dr. Reddy’s


The Vasostrict brand had US. sales of approximately $878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health.

Dr. Reddy’s vasopressin injection is supplied in a carton of 25 single-dose vials each containing vasopressin 1 mL at 20 units/mL.